Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yang Xie, Yan Wang, Shangfei Jiang, Xiaohong Xiang, Jianhua Wang & Linhong Ning. (2022) Novel strategies for the fight of Alzheimer’s disease targeting amyloid-β protein. Journal of Drug Targeting 30:3, pages 259-268.
Read now
Read now
Sheila A Doggrell. (2021) Still grasping at straws: donanemab in Alzheimer’s disease. Expert Opinion on Investigational Drugs 30:8, pages 797-801.
Read now
Read now
Articles from other publishers (12)
David A. Loeffler. (2023) Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects. Journal of Alzheimer's Disease Reports 7:1, pages 873-899.
Crossref
Crossref
David A. Loeffler. (2023) Experimental approaches for altering the expression of Abeta‐degrading enzymes. Journal of Neurochemistry 164:6, pages 725-763.
Crossref
Crossref
Nicole Shu Ling Yeo-Teh & Bor Luen Tang. (2023) A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer’s Disease. Science and Engineering Ethics 29:1.
Crossref
Crossref
Gouri Chopra, Shabnam Shabir, Sumaira Yousuf, Simran Kauts, Shahnawaz A. Bhat, Ashiq H. Mir & Mahendra P. Singh. (2022) Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases. Molecular Neurobiology 59:12, pages 7513-7540.
Crossref
Crossref
Tarek Zieneldien, Janice Kim, Darrell Sawmiller & Chuanhai Cao. (2022) The Immune System as a Therapeutic Target for Alzheimer’s Disease. Life 12:9, pages 1440.
Crossref
Crossref
Gustavo Alves Andrade dos Santos. 2022. Pharmacological Treatment of Alzheimer's Disease. Pharmacological Treatment of Alzheimer's Disease
1
14
.
Panpan Zhang, Ze Wang, Chenye Mou, Jiamei Zou, Yanfei Xie, Zhiwen Liu, C. Benjamin Naman, Yuechun Mao, Jiaxin Wei, Xinghan Huang, Jiahui Dong, Mengxiang Yang, Ning Wang, Haixiao Jin, Fufeng Liu, Dongdong Lin, Hao Liu, Fei Zhou, Shan He, Bin Zhang & Wei Cui. (2021) Design and synthesis of novel tacrine-dipicolylamine dimers that are multiple-target-directed ligands with potential to treat Alzheimer’s disease. Bioorganic Chemistry 116, pages 105387.
Crossref
Crossref
Ibrahim Mortada, Raymond Farah, Sanaa Nabha, David M. Ojcius, Youssef Fares, Wassim Y. Almawi & Najwane Said Sadier. (2021) Immunotherapies for Neurodegenerative Diseases. Frontiers in Neurology 12.
Crossref
Crossref
Allison B. Reiss, Natalie Montufar, Joshua DeLeon, Aaron Pinkhasov, Irving H. Gomolin, Amy D. Glass, Hirra A. Arain & Mark M. Stecker. (2021) Alzheimer Disease Clinical Trials Targeting Amyloid. The Neurologist 26:2, pages 52-61.
Crossref
Crossref
Kevin Mullane & Michael Williams. (2020) Alzheimer’s disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?. Biochemical Pharmacology 177, pages 113945.
Crossref
Crossref
Gabor G Kovacs. (2019) Molecular pathology of neurodegenerative diseases: principles and practice. Journal of Clinical Pathology 72:11, pages 725-735.
Crossref
Crossref
Leon Stefanovski, Paul Triebkorn, Andreas Spiegler, Margarita-Arimatea Diaz-Cortes, Ana Solodkin, Viktor Jirsa, Anthony Randal McIntosh & Petra Ritter. (2019) Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease. Frontiers in Computational Neuroscience 13.
Crossref
Crossref